evipedia.ai
← Back

Lipoic Acid Trisulfide for Muscle Preservation

Evidence Review created on 09/19/2026 using AI4L / Opus 5

Also known as: LASSS, LATS, α-Lipoic Acid Trisulfide, R-Lipoic Acid Trisulfide, Trisulfur Lipoic Acid, TR-LA, 1,2,3-Trithiane-4-pentanoic Acid

Motivation

Lipoic acid trisulfide is a laboratory-made relative of lipoic acid — the sulfur compound the body uses in energy metabolism, sold widely as a supplement. The difference is a single extra sulfur atom tucked inside its ring. That loosely held sulfur makes the molecule unusually reactive: it hands sulfur to proteins and releases hydrogen sulfide, a gas the body itself uses as a signal.

Skeletal muscle holds a reserve of stem cells that are woken by a signal protein stored in the scaffolding around muscle fibres. With age, and with prolonged inactivity, that protein is chemically altered exactly where it docks onto the stem cells, so the call to repair is never delivered. Work from a Japanese university group reports that lipoic acid trisulfide both shields the signal from this alteration and appears to sharpen it.

This review examines lipoic acid trisulfide as a means of preserving skeletal muscle: how it is proposed to act, what the available laboratory and animal work does and does not establish, the safety questions inherited from its parent compound and from sulfur chemistry, the obstacles to obtaining it, and what would have to be measured to judge any effect.

Benefits - Risks - Protocol - Conclusion

This section lists sources that give a substantive overview of lipoic acid trisulfide, its chemistry, and the muscle-repair signalling pathway it is proposed to act on.

Only four sources qualify. Lipoic acid trisulfide has been the subject of a handful of primary papers since 2024, and no eligible blog post, podcast episode or lecture discusses it; the list was not padded with material about the parent compound. No content on lipoic acid trisulfide was found on any of the priority expert platforms, because the compound is investigational and was first linked to muscle in July 2026, after their most recent lipoic acid coverage.

Grokipedia

No Grokipedia article exists for lipoic acid trisulfide. The closest page on the site covers α-lipoic acid, the two-sulfur parent compound, which is a different molecule and does not address the trisulfide.

Examine

No Examine article exists for lipoic acid trisulfide. Examine covers α-lipoic acid, the two-sulfur parent compound, but has no page, study summary or database entry for the trisulfide.

ConsumerLab

No ConsumerLab article exists for lipoic acid trisulfide. ConsumerLab tests and reviews α-lipoic acid products, but the trisulfide is not sold as a consumer supplement and is therefore absent from its testing programme.

Systematic Reviews

No systematic reviews or meta-analyses for Lipoic Acid Trisulfide were found on PubMed as of 19 September 2026.

Neither side is represented: no systematic review or meta-analysis covers the claimed muscle-stem-cell effect, and none covers the principal risk inherited from the parent compound.

Mechanism of Action

Lipoic acid trisulfide is α-lipoic acid (a sulfur-containing cofactor of fuel-burning enzymes) with a third sulfur inserted into its ring, giving a six-membered 1,2,3-trithiane ring. That loosely bound extra “sulfane” sulfur makes it a hydrogen sulfide (H₂S — a gas the body makes as a signal) donor and a modifier of protein sulfur bridges.

The first mechanism is protective. Hepatocyte growth factor (HGF — the signal that wakes resting muscle stem cells) is stored in the extracellular matrix that surrounds muscle fibres. Peroxynitrite (ONOO⁻ — formed when nitric oxide meets superoxide) adds nitro groups to HGF at tyrosines 198 and 250, the surface it uses to dock onto receptor c-Met, so stem cells are never called. Trisulfides block that step.

The second is a gain of function. Above a 1:4000 molar ratio the trisulfide appears to remodel internal sulfur bridges behind tyrosine 198, reshaping HGF to bind c-Met more than twice as tightly and resist nitration. Neither the two-sulfur parent nor glutathione trisulfide does this, implicating the ring structure, not antioxidant strength.

A competing reading attributes any muscle effect to hydrogen sulfide itself, which adds sulfur to proteins and activates AMPK (a cellular energy sensor) to restore autophagy (cellular self-clearing).

Pharmacological properties: No human data exist. Reduction releases lipoic acid, about 30% orally bioavailable, half-life well under an hour, cleared by liver S-methylation and β-oxidation, not by cytochrome P450 drug-metabolising enzymes (Teichert et al., 2003); surplus sulfur is cleared by mitochondrial sulfide:quinone oxidoreductase. Selectivity and tissue distribution are unpublished.

Historical Context & Evolution

Lipoic acid was isolated in 1951 and adopted in Germany under the name thioctic acid as an intravenous and oral treatment for diabetic nerve damage, a use still supported by controlled trials such as the four-month cardiac autonomic neuropathy (nerve damage affecting heart-rate control) study of Ziegler et al., 1997. Its original rationale was metabolic and antioxidant, not muscular.

Two separate lines of work converged on the trisulfide. The first was the emergence of hydrogen sulfide as a signalling molecule in the 2000s, which drew attention to compounds carrying extra “sulfane” sulfur; Japanese groups studied glutathione trisulfide in this context, and chemists at Kyowa Pharma Chemical and Meijo University reported in 2024 the first gram-scale, above-99%-pure synthesis of the trisulfide plus cyclodextrin complexes that made it water-soluble and heat-stable enough for development (Tomonaga et al., 2024).

The second line was the muscle-loading research programme at Kyushu University, which established that mechanical stimulation releases HGF from the matrix to activate muscle stem cells, then showed that this signal is nitrated with age at the two tyrosines it uses to bind its receptor (Elgaabari et al., 2024). That finding reframed age-related muscle loss as a damaged-signal rather than a missing-signal problem, and prompted an antibody-based attempt to shield the signal (Tanaka et al., 2024) before the trisulfide was tried in 2026.

No part of this history has been retracted or dismissed; what changed is the interpretation of why the repair signal fails, and that shift rests on the nitration measurements.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the entire evidence base is in-vitro receptor-binding and stem-cell labelling assays plus one rodent immunofluorescence endpoint, with no human clinical endpoint and no clinically validated surrogate measured in any trial.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single human trial and no observational human cohort of any size that has measured a clinical outcome or a validated surrogate with lipoic acid trisulfide.

Low 🟩

Speculative 🟨

Preservation of Muscle Stem Cell Activation Signalling

Trisulfide pre-treatment blocked nitration at both docking tyrosines and restored stem-cell cycle entry in rat culture. Oral dosing prevented disuse nitration in mouse calf muscle. Basis is mechanistic only (Zushi et al., 2026).

Supranormal Receptor Binding of the Repair Signal

At a 1:8000 molar ratio the repair signal bound its receptor over twice as tightly, persisting after filtration. No study in any species tested whether this reaches muscle. Mechanistic only (Zushi et al., 2026).

Sulfane Sulfur and Hydrogen Sulfide Supply to Aged Muscle

Each trisulfide unit theoretically yields one hydrogen sulfide molecule (Guo et al., 2025). Donors enlarge fibre cross-section and suppress muscle-breakdown enzymes in aged rodents (Yang et al., 2024). Evidence is preclinical only.

Broad Resistance to Protein Nitration ⭕️ Not Central to Muscle Preservation

Serum albumin treated with the compound also resisted nitration, suggesting general rather than muscle-specific chemistry. This bears on cumulative protein damage across tissues, not muscle mass. One in-vitro observation (Zushi et al., 2026).

Antitumour Activity of Sulfide Release ⭕️ Not Central to Muscle Preservation

Cross-linked trisulfide nanoparticles inhibited tumour growth by 83% in animals through sustained sulfide release, outperforming a standard chemotherapy drug. This bears on oncology, not muscle mass. Preclinical only (Guo et al., 2025).

Blood-Pressure and Kidney Protection ⭕️ Not Central to Muscle Preservation

A polymerised trisulfide lowered blood pressure and markers of kidney injury in animals, surpassing a standard blood-pressure drug. This bears on cardiovascular and kidney endpoints, not muscle mass. Preclinical only (Shao et al., 2026).

Benefit-Modifying Factors

  • Baseline nitrative burden: Benefit is predicated on the repair signal already being damaged. Individuals with low peroxynitrite exposure — younger, non-diabetic, non-smoking, well-conditioned — have less altered signal available to rescue and therefore less theoretical headroom.

  • Fibre-type composition: Nitration of the repair signal is reported predominantly on fast-twitch fibres, and the mouse effect was seen in calf muscles. Individuals whose training and function depend on explosive fast-twitch output are the theoretical beneficiaries.

  • Mechanical loading: The repair signal is only released from the matrix when muscle is stretched or loaded. Without resistance or eccentric (muscle-lengthening) loading there is little released signal for the compound to protect, making loading a precondition.

  • Sex: No sex comparison exists. Every published experiment used male rats and male mice, chosen for stem cell yield, so any sex difference in benefit is entirely unknown rather than absent.

  • Age: Nitration of the repair signal accumulates with age, so the proposed benefit should be larger in older adults. The only animal work used 8-week-old mice and 9–10-month-old rats, neither of which models an aged human.

  • Pre-existing health conditions: Conditions that raise nitrative stress — type 2 diabetes, chronic obstructive pulmonary disease, chronic kidney disease, prolonged bed rest — would increase altered signal and, in principle, the room for benefit. None has been studied here.

  • Genetic polymorphisms: No variant has been tested as a benefit modifier. Variants in MET (the gene for the receptor the signal docks onto) and in the nitric oxide synthase genes are the mechanistically obvious candidates and remain unexamined.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no documented adverse event, clinical endpoint or validated surrogate has been recorded in any human exposed to lipoic acid trisulfide, in any trial, because no human exposure has been reported.

Medium 🟥 🟥

No risk reaches Medium either: there is no single human trial and no consistent observational human data on this compound, so even a one-trial adverse-event signal is unavailable.

Low 🟥

Insulin Autoimmune Syndrome

Lipoic acid triggers antibodies against the body’s own insulin in susceptible people, causing hypoglycaemia (low blood sugar) hours to weeks after exposure. Evidence is 49 published case reports, 37 of them pooled in one analysis; all resolved after withdrawal. Indirect here: the trisulfide releases lipoic acid but is untested.

Magnitude: In the 37-patient series, median blood glucose at onset was 2.19 mmol/L, insulin was at or above 100 μIU/mL in 94.6% and insulin autoantibodies were positive in all; resolution took 5 days to 8 months (Li et al., 2021). The 49 case reports were assessed by the European Food Safety Authority — a public regulator that derives no revenue from the conclusion it reached, in contrast to the manufacturers supplying the trisulfide — which estimated the syndrome’s incidence at 0.017 per 100,000 in Japan in 2017–2018 and could define no safe dose (EFSA Panel on Nutrition, Novel Foods and Food Allergens et al., 2021).

Blunting of Training-Induced Vascular and Functional Adaptation ⚠️ Conflicted

A controlled human study found an antioxidant load containing lipoic acid abolished blood-pressure and endothelial gains from six weeks of training in older men; other work finds no such interference, and the trisulfide’s own effect is nitration-independent. Net reading: a dose- and timing-dependent hazard for trainees, not a general one.

Magnitude: Six weeks of knee-extensor training lowered systolic pressure from 150 to 138 mmHg, diastolic from 91 to 79 mmHg and raised flow-mediated vasodilation from 1.5% to 4.9%; an acute antioxidant dose including lipoic acid returned all three toward baseline in six trained older hypertensive men (Wray et al., 2009).

Gastrointestinal Intolerance and Nausea

Lipoic acid is an acid and causes dose-dependent nausea, upper abdominal discomfort and reflux in oral trials; sulfur donors add sulfurous belching and flatulence. Effects reverse on dose reduction. Indirect here: the trisulfide is untested and may differ, releasing hydrogen sulfide in the gut.

Magnitude: Direction only: nausea, vomiting and vertigo increased dose-dependently across 600, 1,200 and 1,800 mg daily of the parent compound over 5 weeks, with 600 mg identified as the best risk-to-benefit dose; the literature reports no incidence figure for these events (Ziegler et al., 2006).

Speculative 🟨

Mitochondrial Respiratory Inhibition from Sulfide Overload

Hydrogen sulfide inhibits cytochrome c oxidase (the terminal enzyme of the respiratory chain) above a narrow concentration window, and sustained donor exposure disrupts mitochondrial structure in rodents. Basis is animal and in-vitro toxicology only.

Stimulation of the c-Met Growth Pathway

The receptor made to bind the repair signal more tightly also drives several cancers, so a supranormal signal is theoretically pro-proliferative. No study has looked. Basis is mechanistic reasoning from the paper’s own findings.

Non-Specific Remodelling of Protein Sulfur Bridges

The proposed action is chemical alteration of internal sulfur bridges, and the same alteration occurred on serum albumin. Off-target modification of other bridge-dependent proteins is plausible and entirely uncharacterised.

Unknown Chronic Toxicology and Impurity Profile

No repeat-dose toxicology, genotoxicity, reproductive or carcinogenicity study of lipoic acid trisulfide has been published. The absence of data is not evidence of safety; basis is the published chemistry alone.

Risk-Modifying Factors

  • HLA class II genotype: Insulin autoimmune syndrome after lipoic acid clusters in carriers of HLA-DRB1*04:06 and *04:03 (variants of the genes that present antigens to the immune system), which cannot be identified without genetic testing.

  • Sulfur clearance genotype: Loss-of-function variants in ETHE1 or SQOR (the two enzymes that dispose of surplus sulfur) would let sulfide accumulate from a trisulfide donor. Neither has been tested.

  • Baseline glucose and insulin: Low-normal fasting glucose, high fasting insulin, or existing insulin or sulfonylurea therapy (sulfonylureas make the pancreas release insulin) raises the consequence of any added glucose-lowering effect from mild symptoms to a dangerous event.

  • Sex: Published lipoic acid autoimmune cases are predominantly female — 28 of 37 in the largest pooled analysis. Whether that reflects exposure or susceptibility is unresolved, and no animal safety work included females.

  • Pre-existing health conditions: Active or recent malignancy, thiamine deficiency, heavy alcohol use, advanced liver disease and impaired kidney function each plausibly amplify risk, through growth signalling, sulfur metabolism or reduced clearance respectively.

  • Age: Older adults carry more polypharmacy, blunted counter-regulation of low blood sugar and reduced liver first-pass capacity, all of which raise the consequence of an adverse event rather than its frequency.

Key Interactions & Contraindications

  • Insulin and sulfonylureas (glimepiride, gliclazide, glipizide): Caution, or absolute contraindication where insulin autoantibodies are present. Consequence is severe hypoglycaemia. Mitigation: frequent glucose monitoring and pre-emptive downward adjustment of the glucose-lowering agent.

  • Levothyroxine and other thyroid replacement: Caution. Sulfur-rich chelating compounds can reduce absorption of the hormone, lowering effective dose. Mitigation: separated administration by at least four hours and a thyroid-stimulating hormone recheck six weeks after starting.

  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, apixaban, warfarin): Caution. Hydrogen sulfide donors inhibit platelet aggregation, so bleeding risk may be additive. Mitigation: monitoring for bruising and mucosal bleeding; no dose change is established.

  • Nitrovasodilators and PDE5 inhibitors (vessel-relaxing drugs: nitroglycerin, isosorbide, sildenafil, tadalafil): Caution. Hydrogen sulfide also relaxes vascular smooth muscle, risking symptomatic hypotension (low blood pressure). Mitigation: separated dosing by several hours; no combined use before exertion.

  • Platinum chemotherapy (cisplatin, carboplatin, oxaliplatin): Absolute contraindication during treatment. Sulfur-rich compounds bind platinum and may reduce antitumour activity. Mitigation: no concurrent use until the treatment course is complete.

  • Antacids, proton pump inhibitors and H₂ blockers (acid-suppressing agents: omeprazole, famotidine, calcium carbonate): Caution. Raised gastric acidity alters dissolution of an acidic sulfur compound, changing absorption unpredictably. Mitigation: constant dosing conditions rather than alternating ones.

  • Mineral supplements (iron, calcium, magnesium, zinc, copper): Caution. Sulfur groups bind divalent metals, reducing absorption of both. Mitigation: separation by at least two hours, with minerals taken with food and the compound fasted.

  • Other hydrogen sulfide and sulfane sulfur donors (garlic-derived polysulfides, glutathione trisulfide, glucoraphanin, sulforaphane, N-acetylcysteine): Caution — additive sulfur load with additive hypotensive and gastrointestinal effects. Mitigation: no stacking; a single sulfur donor only.

  • α-Lipoic acid supplements and benfotiamine-lipoic acid combinations: Caution. Duplicate exposure to the parent compound raises autoimmune-insulin and hypoglycaemia risk without adding trisulfide-specific effect. Mitigation: discontinuation of separate lipoic acid products.

  • Glucose-lowering supplements (berberine, chromium picolinate, cinnamon extract, bitter melon): Caution, additive with the parent compound’s insulin-sensitising effect; consequence is hypoglycaemia. Mitigation: staggered introduction by two weeks with fasting-glucose monitoring.

  • Biotin and other substrates of the sodium-dependent multivitamin transporter: Caution, theoretical only. Lipoic acid shares this uptake route, so sustained high intake may compete with biotin absorption. Mitigation: adequate dietary biotin; no monitoring test is established.

  • Other interventions — resistance and eccentric loading: Potentiating rather than adverse, and the only intervention known to release the repair signal the compound acts on. No separation or dose adjustment applies; loading is the enabling condition.

Populations who should avoid Lipoic Acid Trisulfide:

  • Anyone with active malignancy, or a malignancy treated within the last 5 years, particularly MET-amplified (extra copies of the receptor gene) gastric, lung or renal tumours
  • Carriers of HLA-DRB1*04:06 or *04:03, and anyone with a prior episode of insulin autoimmune syndrome from any cause
  • People taking insulin or a sulfonylurea who cannot monitor glucose frequently
  • Pregnant and lactating women, for whom no reproductive toxicology exists
  • Children and adolescents under 18 years
  • People with a known sulfur-metabolism disorder, including ETHE1 deficiency (ethylmalonic encephalopathy) and documented sulfide-clearance impairment
  • People with severe liver impairment (Child-Pugh Class C, the most advanced grade of liver failure) or estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Anyone with thiamine deficiency or an alcohol use disorder until thiamine status is repleted

Risk Mitigation Strategies

  • Genotyping before exposure: HLA-DRB1*04:06 and *04:03 testing identifies the population in which the parent compound’s autoimmune insulin reaction concentrates, and is the only way to screen for it, since the reaction cannot be predicted clinically.

  • Low starting dose with slow escalation: Beginning at roughly one quarter of any target dose and holding each step for 1–2 weeks limits the severity of a first hypoglycaemic or gastrointestinal event and allows withdrawal before antibodies establish.

  • Capillary glucose monitoring during the first 8 weeks: Fasting and late-postprandial readings, plus any reading during symptoms, catch the hypoglycaemia that defines the autoimmune insulin reaction, which most often appears at night or in early morning.

  • Immediate discontinuation on unexplained hypoglycaemia: Every published case of the autoimmune insulin reaction resolved after the parent compound was stopped, within 5 days to 8 months, so stopping is the definitive mitigation rather than dose reduction.

  • Dosing separated from minerals and thyroid hormone: A two-hour gap from iron, calcium, magnesium and zinc and a four-hour gap from levothyroxine prevents the binding-driven loss of absorption that would otherwise reduce both agents’ effect.

  • Exclusion of active and recent malignancy: Because the compound strengthens binding at a receptor that drives several tumours, oncological clearance and a 5-year disease-free interval mitigate the theoretical proliferative hazard before any exposure.

  • Dosing away from training sessions: Placing any dose at least 4–6 hours from resistance or endurance work limits the antioxidant interference with training adaptation seen with lipoic acid-containing antioxidant loads in older trainees.

  • Single sulfur donor only: Discontinuing garlic extract, N-acetylcysteine, sulforaphane and separate lipoic acid products prevents additive sulfur load, which is the pathway to hypotension, gastrointestinal upset and respiratory-chain inhibition.

  • Baseline and 12-week liver and muscle enzymes: Alanine aminotransferase and creatine kinase before starting and at 12 weeks detect the liver and muscle injury that has never been excluded for this compound in any species.

Therapeutic Protocol

  • No established human protocol: Lipoic acid trisulfide has no approved or practitioner-established regimen. No clinic, compounding pharmacy or published expert protocol uses it, and nothing below constitutes a validated dosing scheme.

  • Only tested regimen: Tatsumi’s laboratory at Kyushu University gave approximately 50 μg per gram body weight per day in drinking water for 3 days, then withdrew it before 5 days of hindlimb unloading in male mice.

  • Human-equivalent estimate: Body-surface-area scaling of that 50 mg/kg mouse dose gives roughly 4 mg/kg daily, about 280 mg for a 70 kg adult. This is an arithmetic conversion, not a tested human dose.

  • Competing approach — parent compound plus loading: The conventional alternative, popularised by Ziegler’s German thioctic acid programme, is 600 mg oral α-lipoic acid daily with progressive resistance training and 1.2–1.6 g/kg dietary protein.

  • Competing approach — dietary sulfane sulfur: An alternative supplies the sulfur donor from food: garlic-derived polysulfides and glucoraphanin from cruciferous vegetables, the route examined in cell models of muscle ageing by Micheli’s group in Florence.

  • Best time of day: Untested. The parent compound is conventionally taken 30 minutes before the first meal because food reduces its absorption, and morning dosing keeps any glucose-lowering effect during waking hours when symptoms are noticed.

  • Half-life: The trisulfide’s own half-life is unpublished. Released lipoic acid clears with a plasma half-life well under an hour and shows no accumulation over four days of once-daily 600 mg dosing.

  • Single versus split dosing: The animal work used continuous exposure via drinking water. Split dosing is the mechanistically consistent choice given short parent-compound persistence, but no comparison of single against divided administration exists.

  • Genetic polymorphisms: HLA-DRB1*04:06 and *04:03 carriers face the autoimmune insulin hazard, which places them outside any dosing rationale. ETHE1 and SQOR variants impair sulfur disposal and argue for a lower ceiling; neither has been studied pharmacogenetically.

  • Sex differences: None documented. All published dosing was in male animals, so no sex-specific dose, response or efficacy difference can be stated, and female-specific dosing has no basis.

  • Age considerations: The mechanism predicts greater effect in older adults, who carry more altered repair signal. Against that, adults above 70 have reduced liver first-pass capacity and blunted counter-regulation of low blood sugar, favouring the lowest workable dose.

  • Baseline biomarkers: Fasting glucose and insulin determine hypoglycaemia headroom; appendicular lean mass and grip strength define whether there is measurable deficit to address. Altered repair signal itself cannot be measured clinically.

  • Pre-existing health conditions: Type 2 diabetes, chronic kidney disease and chronic obstructive pulmonary disease raise nitrative stress and theoretically the response, but each also raises risk, so they shift the risk-benefit rather than the dose.

Discontinuation & Cycling

  • Pulsed rather than lifelong: The only tested pattern was a 3-day loading course stopped before the atrophy stimulus began, making this an intermittent intervention by design rather than a continuous one.

  • Effect outlasts exposure: Protection persisted through 5 days of disuse after dosing stopped, because the chemically enhanced repair signal remains until it is metabolically turned over. Duration in humans is unknown.

  • No withdrawal effects known: No rebound, dependence or withdrawal phenomenon has been reported for the trisulfide or for the parent compound, though total human exposure to the trisulfide is zero.

  • Tapering not applicable: With no dependence mechanism and a short parent-compound half-life, abrupt cessation carries no known hazard. Autoimmune hypoglycaemia can appear or persist after stopping, so the hazard window extends beyond the last dose.

  • Cycling is mechanistically plausible: Because the effect is carried by modified repair signal rather than by circulating compound, cycles matched to loading blocks or bed-rest periods are coherent, but no cycle length has been tested.

  • Stopping rules: Immediate and permanent discontinuation applies on unexplained hypoglycaemia, new malignancy diagnosis, or unexplained rises in liver or muscle enzymes, none of which warrants a dose reduction instead.

Sourcing and Quality

  • Not a consumer product: Lipoic acid trisulfide is an investigational chemical, not a dietary supplement or a medicine. No retail or pharmacy product contains it, and no compounding pharmacy lists it as an available active.

  • Label confusion with the parent compound: Products labelled lipoic acid, α-lipoic acid, R-lipoic acid or thioctic acid contain the two-sulfur disulfide, which failed to reproduce the trisulfide’s effect in the same experiments. They are not substitutes.

  • Known synthetic source: The material used in the published work came from Kyowa Pharma Chemical in Toyama, Japan, identified as the R-enantiomer, CAS registry number 1204245-29-3, and supplied at above 99% purity.

  • What to look for: A certificate of analysis specifying the R-enantiomer, above 99% purity by chromatography, residual solvent limits, and confirmation of the three-sulfur ring by nuclear magnetic resonance or Raman spectroscopy rather than by mass alone.

  • Formulation matters: The free compound is poorly water-soluble and heat-unstable. β-Cyclodextrin encapsulation raised both solubility and thermal stability substantially, so an unencapsulated powder is likely to degrade in storage.

  • Third-party testing: No independent testing programme covers this compound. Certification schemes such as NSF, Informed Choice and USP verify supplements only, so no consumer-facing purity assurance exists at present.

  • Research-grade purchase is the practical failure point: Material offered by chemical resellers without an enantiomeric purity statement may be racemic or partly the disulfide, and carries no manufacturing quality system intended for human ingestion.

Practical Considerations

  • Time to effect: Unknown in humans. In mice the protective chemistry was present after 3 days of dosing, but the endpoint measured was a chemical marker; any change in human muscle mass or strength would take months to appear.

  • Common pitfall — substituting the parent compound: The commonest error is buying α-lipoic acid instead. The published experiments used the disulfide as a negative control and it produced no receptor-affinity or nitration-resistance effect.

  • Common pitfall — expecting mass gain without loading: The mechanism protects a signal that only appears when muscle is mechanically loaded. Without resistance or eccentric work there is no released signal to protect, so the intervention has nothing to act on.

  • Common pitfall — stacking sulfur donors: Adding garlic extract, N-acetylcysteine or sulforaphane in the belief that more sulfur is better raises sulfur load toward the range where respiratory-chain inhibition and hypotension occur.

  • Regulatory status: Not approved as a medicine in any jurisdiction and not notified as a new dietary ingredient in the United States or as a novel food in the European Union. Any human use is unregulated self-experimentation.

  • Cost and accessibility: Access is the binding constraint. The compound is available only as research-grade material at research-grade pricing, with no clinical supply chain, which places it far outside normal supplement cost and availability.

  • Payer incentives: Resistance training and dietary protein cost a fraction of any novel compound, giving insurers and national health systems a structural reason to favour them and little reason to fund trials of a proprietary sulfur molecule — a plausible bias in what gets tested.

Interaction with Foundational Habits

  • Sleep: No established interaction in either direction; neither the trisulfide nor its parent has a documented effect on sleep architecture. The practical point runs the other way: the autoimmune insulin reaction linked to the parent compound typically presents at night or early morning, so unexplained night waking with sweating warrants a glucose measurement.

  • Nutrition: Direct and two-sided. Food lowers absorption of the released parent compound, so fasted dosing 30 minutes before the first meal is conventional. Adequate protein, 1.2–1.6 g per kg daily, is the precondition for repair, since the mechanism activates stem cells rather than supplying substrate. Garlic and cruciferous vegetables add to total sulfur load.

  • Exercise: Directly potentiating. Mechanical stretch and eccentric loading release the repair signal from the matrix, so resistance training is the trigger for this mechanism rather than an add-on. Against that, an antioxidant load containing the parent compound abolished training gains in older men (Wray et al., 2009), favouring a 4–6 hour separation from dosing.

  • Stress management: Indirect. The damage the compound is meant to prevent comes from peroxynitrite, generated when inflammatory and sympathetic activation raise nitric oxide and superoxide together. Measures that lower chronic inflammatory and sympathetic load — sufficient sleep, aerobic conditioning, reduced alcohol intake — cut the substrate for that damage.

Monitoring Protocol & Defining Success

Because no human has been dosed, monitoring cannot be validated and must be constructed from the parent compound’s documented hazards and from the outcome the intervention targets. Before any exposure, the sensible baseline set covers glucose handling, the organs that clear the compound, muscle integrity, and the muscle measures that define success. That means fasting glucose, glycated haemoglobin, fasting insulin and C-peptide, alanine aminotransferase, creatine kinase, and a body-composition scan with grip strength. Insulin autoantibodies sit outside the baseline set, their value lying in rapid availability once symptoms appear.

Ongoing testing is front-loaded to the period when the autoimmune insulin reaction appears: glucose and symptom review at 2 weeks and 4 weeks, the full glucose and enzyme panel at 12 weeks, then every 6 months. Body composition and strength are repeated at 6 and 12 months, since nothing shorter can register a real change in muscle.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–86 mg/dL (3.9–4.8 mmol/L) Detects the glucose-lowering effect carried by the released parent compound Requires an 8–12 hour fast and is best paired with fasting insulin; conventional range runs to 99 mg/dL, which misses early drift
HbA1c 4.8–5.4% Tracks glucose control over months rather than at one moment HbA1c is glycated haemoglobin, a three-month average of blood sugar; conventional normal extends to 5.6%, well above this target; falsely low when red-cell lifespan is shortened
Fasting insulin 2–5 μIU/mL Very high insulin with low glucose points to insulin autoantibodies rather than a pancreatic tumour Conventional range extends to 25 μIU/mL; drawn in the same tube as C-peptide
C-peptide 1.0–2.0 ng/mL Separates an autoantibody-driven reaction from injected insulin as the cause of low glucose Conventional range runs about 0.8–3.9 ng/mL; interpretable only when drawn during a symptomatic episode
Insulin autoantibodies (IAA) Negative The defining test for the autoimmune insulin reaction linked to the parent compound IAA are antibodies against the body’s own insulin; relevant only once hypoglycaemic symptoms occur, not as routine surveillance
Creatine kinase (CK) 60–200 U/L Flags muscle injury that would otherwise confound any muscle endpoint CK is an enzyme released by damaged muscle; uninterpretable within 72 hours of hard resistance training
Alanine aminotransferase (ALT) 10–26 U/L (men), 10–19 U/L (women) The released parent compound undergoes heavy first-pass liver handling ALT is a liver enzyme; the conventional upper limit near 40–50 U/L is far less sensitive to early change
Appendicular lean mass index (ALMI) Above 7.0 kg/m² (men), above 5.5 kg/m² (women) The outcome the intervention is meant to preserve ALMI is arm and leg lean mass divided by height squared, measured by dual-energy X-ray absorptiometry; comparable only across scans on the same machine and in the same hydration state
Plasma total sulfane sulfur No established target range; track the change from the individual’s own baseline instead The only direct read-out of trisulfide exposure Research assay only, not offered by clinical laboratories; the signal is lost unless samples are processed immediately

Qualitative markers worth tracking alongside the laboratory panel:

  • Grip strength, chair-rise time and usual gait speed, which change before lean mass does
  • Perceived recovery and soreness resolution after resistance sessions
  • Energy levels and exercise tolerance across a training block
  • Symptoms of low blood sugar: night sweats, early-morning waking, tremor, confusion after fasting
  • Sulfurous taste, breath or flatulence, which indicate sulfur load
  • Digestive comfort, reflux and appetite

Emerging Research

  • No registered trial exists: A ClinicalTrials.gov search for lipoic acid trisulfide on 19 September 2026 returned zero records. No interventional or observational study of the compound is registered anywhere, in any phase, for any indication.

  • Aging-animal studies are the stated next step: The authors of the muscle work state they have not shown the compound mitigates age-related muscle loss and that aged-animal experiments are required (Zushi et al., 2026). Those results would strengthen or collapse the case.

  • Nearest registered human work: NCT05848830 is a Phase 3, 60-participant trial in myotonic dystrophy type 1 (a rare inherited muscle-wasting disease) of home-based training plus a multi-ingredient supplement containing α-lipoic acid, with body composition and peak oxygen uptake as primary endpoints; registry status is unknown.

  • Oral delivery platform: A polymerised trisulfide achieved sustained hydrogen sulfide and lipoic acid release over 60 hours with markedly improved oral pharmacokinetics in mice (Shao et al., 2026). This addresses the short parent-compound half-life that limits any human protocol.

  • Evidence that could weaken the case: The same chemistry achieved 83% tumour inhibition as a cytotoxic agent (Guo et al., 2025). A molecule potent enough to kill tumour cells through sulfide release is not obviously benign taken chronically.

  • Competing strategy against the same target: An antibody approach shields the repair signal from nitration without introducing a reactive sulfur compound (Tanaka et al., 2024). If it advances first, the trisulfide route may be bypassed rather than disproven.

  • Chemistry still being settled: Stereochemical and spectroscopic characterisation of the three-sulfur ring, including recovery of lipoic acid from it, was published only in 2026 (Matsugo et al., 2026), which indicates how early the material science remains.

  • Open question on the mechanism itself: The chemical modification, the modified residues and the structural change all remain unidentified by the authors’ own account. Until they are, the effect cannot be engineered, dose-optimised, or distinguished from an assay artefact.

Conclusion

Lipoic acid trisulfide is a sulfur-enriched version of lipoic acid, and the case for it in muscle preservation rests on an appealing but very early idea: that the signal which wakes resting muscle stem cells is not missing in older muscle but chemically spoiled, and that this particular molecule both prevents the spoiling and leaves the signal working better than it did before. That claim currently stands on cell-culture work, on receptor-binding measurements, and on a short mouse experiment in which only the chemical marker of damage was measured, not muscle size or strength. No human has been studied. The researchers who reported the effect state plainly that they have not shown the compound treats age-related muscle loss.

The risk picture is inherited rather than measured. Lipoic acid itself carries a small but real link to an autoimmune reaction against the body’s own insulin that causes dangerously low blood sugar, and sulfur-donating compounds bring their own theoretical concerns, including interference with the machinery cells use to make energy and the possibility of strengthening a growth signal that some tumours exploit. None of this has been assessed for the trisulfide.

The evidence base is narrow in origin: nearly all of it comes from one university group and the chemical manufacturers that supply the material, a concentration of interest worth naming. Obtaining the compound remains a research-grade proposition rather than a consumer one, and the mechanism’s enabling condition — mechanical loading of muscle — is available without it.

Top - Benefits - Risks - Protocol